Cargando…

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

BACKGROUND: FOLFOX second-line treatment seems to be a validated option for patients with pancreatic cancer (PC) progressing after gemcitabine chemotherapy. However, other therapeutics strategy has developed in first-line therapy, as the FIRGEM phase II study that evaluated gemcitabine alone versus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaanan, Aziz, Trouilloud, Isabelle, Markoutsaki, Theofano, Gauthier, Mélanie, Dupont-Gossart, Anne-Claire, Lecomte, Thierry, Aparicio, Thomas, Artru, Pascal, Thirot-Bidault, Anne, Joubert, Fanny, Fanica, Daniella, Taieb, Julien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075567/ https://www.ncbi.nlm.nih.gov/pubmed/24929865 http://dx.doi.org/10.1186/1471-2407-14-441

Ejemplares similares

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial
por: Anota, Amélie, et al.
Publicado: (2015)

Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
por: Williet, Nicolas, et al.
Publicado: (2019)

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study
por: Aparicio, T, et al.
Publicado: (2013)

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study
por: Mas, Leo, et al.
Publicado: (2019)

Current insights in to the pathophysiology of Irritable Bowel Syndrome
por: Karantanos, Theodoros, et al.
Publicado: (2010)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Multicentre, interventional, single-arm study protocol of telemonitored circadian rhythms and patient-reported outcomes for improving mFOLFIRINOX safety in patients with pancreatic cancer (MultiDom, NCT04263948)
por: Bouchahda, Mohamed, et al.
Publicado: (2023)

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study
por: Pernot, Simon, et al.
Publicado: (2020)

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
por: Lee, Hee Jun, et al.
Publicado: (2013)

Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trial
por: Karoui, Mehdi, et al.
Publicado: (2015)

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX
por: Recchia, F, et al.
Publicado: (2004)

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients
por: Mabro, M, et al.
Publicado: (2006)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Exploring the best treatment options for BRAF-mutant metastatic colon cancer
por: Taieb, Julien, et al.
Publicado: (2019)

Folfox encephalopathy: A rare case series
por: Batra, Ullas, et al.
Publicado: (2017)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial
por: Li, Ting, et al.
Publicado: (2015)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy
por: Porcello Marrone, Luiz Carlos, et al.
Publicado: (2013)

Prevotella contributes to individual response of FOLFOX in colon cancer
por: Hou, Xiao‐Ying, et al.
Publicado: (2021)

Safety study of Folfox-HAIC in relieving bed restriction
por: Zhao, Xiaoyun, et al.
Publicado: (2021)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
por: Tse, Vicki C, et al.
Publicado: (2011)

Fuchs Syndrome: Medical Treatment of 1 Case and Literature Review
por: Gossart, Rémy, et al.
Publicado: (2017)

Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
por: Soon, Wai Cheong, et al.
Publicado: (2014)

FOLFOX Induced Takotsubo Cardiomyopathy Treated with Impella Assist Device
por: Sundaravel, Swethika, et al.
Publicado: (2017)

Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
por: Okada, Shunji, et al.
Publicado: (2017)

Prognostic Nomogram for Advanced Hepatocellular Carcinoma Treated with FOLFOX 4
por: Qin, Shukui, et al.
Publicado: (2017)

Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)

Akkermansia Muciniphila Potentiates the Antitumor Efficacy of FOLFOX in Colon Cancer
por: Hou, Xiaoying, et al.
Publicado: (2021)

A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency
por: Pallet, Nicolas, et al.
Publicado: (2020)

The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318
por: Breakstone, Rimini, et al.
Publicado: (2022)

Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries
por: Lo Dico, Rea, et al.
Publicado: (2020)

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
por: Hamidou, Zeinab, et al.
Publicado: (2016)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
por: Takahashi, Takao, et al.
Publicado: (2022)

Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study
por: Pernot, Simon, et al.
Publicado: (2018)

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study
por: Palle, Juliette, et al.
Publicado: (2017)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_5l81plj57iip4h8lk0hltkblv2